MOREPENLAB

Morepen Laboratories Share Price

 

 

Invest in Morepen Laboratories with 2.83X leverage

Invest with MTF

Performance

  • Low
  • ₹41
  • High
  • ₹42
  • 52 Week Low
  • ₹38
  • 52 Week High
  • ₹81
  • Open Price₹42
  • Previous Close₹42
  • Volume995,862

Investment Returns

  • Over 1 Month -6.71%
  • Over 3 Month -15.51%
  • Over 6 Month -33.73%
  • Over 1 Year -46.55%

Smart Investing Starts Here Start SIP with Morepen Laboratories for Steady Growth!

Invest Now

Morepen Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 22.9
  • PEG Ratio
  • -0.9
  • Market Cap Cr
  • 2,263
  • P/B Ratio
  • 1.9
  • Average True Range
  • 1.32
  • EPS
  • 1.38
  • Dividend Yield
  • 0.5
  • MACD Signal
  • -1.31
  • RSI
  • 43.34
  • MFI
  • 44.55

Morepen Laboratories Financials

Morepen Laboratories Technicals

EMA & SMA

Current Price
₹41.29
-0.31 (-0.75%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹41.89
  • 50 Day
  • ₹44.34
  • 100 Day
  • ₹47.76
  • 200 Day
  • ₹52.27

Resistance and Support

41.43 Pivot Speed
  • R3 42.37
  • R2 42.10
  • R1 41.70
  • S1 41.03
  • S2 40.76
  • S3 40.36

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Morepen Laboratories Ltd. is a leading pharmaceutical company in India, specializing in Active Pharmaceutical Ingredients (APIs), formulations, diagnostics, and over-the-counter (OTC) products. It exports to over 75 countries, with a strong focus on APIs like Loratadine.

Morepen Laboratories has an operating revenue of Rs. 1,755.45 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 9% is okay, ROE of 10% is good. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 35 which is a POOR score indicating inconsistency in earnings, a RS Rating of 14 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Morepen Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-06 Quarterly Results & Others To consider other business matters. per share(10%)Final Dividend
2025-05-12 Audited Results & Final Dividend
2025-02-06 Quarterly Results
2024-11-11 Quarterly Results
Date Purpose Remarks
2025-08-30 FINAL Rs.0.20 per share(10%)Final Dividend
View Morepen Laboratories Dividend History Arrow

Morepen Laboratories F&O

Morepen Laboratories Shareholding Pattern

35.65%
0%
0.94%
1.62%
0.55%
49.96%
11.28%

About Morepen Laboratories

  • NSE Symbol
  • MOREPENLAB
  • BSE Symbol
  • 500288
  • Chairman & Managing Director
  • Mr. Sushil Suri
  • ISIN
  • INE083A01026

Similar Stocks to Morepen Laboratories

Morepen Laboratories FAQs

Morepen Laboratories share price is ₹41 As on 27 December, 2025 | 23:59

The Market Cap of Morepen Laboratories is ₹2262.5 Cr As on 27 December, 2025 | 23:59

The P/E ratio of Morepen Laboratories is 22.9 As on 27 December, 2025 | 23:59

The PB ratio of Morepen Laboratories is 1.9 As on 27 December, 2025 | 23:59

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23